News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
1Bitget UEX Daily | Trump Does Not Rule Out Sending Troops to Iran; Iran Closes Strait of Hormuz, Oil Prices Soar; Drone and Space Stocks Rise Collectively (2026/03/03)2Bitcoin slide slowing, but bear market still in play: Analysts3Research Report｜In-Depth Analysis and Market Cap of Opinion Labs (OPN)
Coherent's Shares Plummet 6.06% After $2B NVIDIA Pact, Trailing 40th in $2.28B Volume
101 finance·2026/03/03 22:27
Bank of America posts stronger-than-expected Q4 results, shares climb 0.32% even with $2.53B volume ranking 35th
101 finance·2026/03/03 22:27
Locals prefer satoshis to dollars, says Africa Bitcoin chair Stafford Masie
Cointelegraph·2026/03/03 22:27
Netflix Gains 0.63% on JPMorgan Upgrade Trading Volume Drops to 15th in 5.68 Billion
101 finance·2026/03/03 22:21
JPMorgan's 0.91% increase places it 21st in $
101 finance·2026/03/03 22:21
Exxon's $3.84 Billion Volume Plummets to 17th as Venezuela Gambit Unfolds
101 finance·2026/03/03 22:21
AMD's 3.86% Stock Drop Amid $7.13B Volume Ranks 11th as AI Push and Export Hurdles Shape Volatility
101 finance·2026/03/03 22:21
Flash
22:25
Data: 10 million MOVE transferred out from Movement Network, worth approximately $2.21 million.ChainCatcher news, according to Arkham data, at 06:19, 10 million MOVE (worth approximately $2.21 million) were transferred from Movement Network to Null Address.
22:14
According to the latest filing submitted to the U.S. Securities and Exchange Commission (SEC), ABVC BioPharma, Inc. has identified significant deficiencies in its internal control over financial reporting for the fiscal year 2025.This disclosure has raised concerns in the market regarding the company's financial transparency and governance structure. The company stated that it is actively taking measures to strengthen its internal control mechanisms in order to improve the accuracy and reliability of its financial information.
22:14
According to the latest filing submitted to the U.S. Securities and Exchange Commission (SEC), ABVC BioPharma, Inc. has identified significant deficiencies in its internal control over financial reporting for the fiscal year 2025.This disclosure has raised concerns in the market regarding the company's financial transparency and governance structure. The company stated that it is actively taking measures to strengthen its internal control mechanisms in order to improve the accuracy and reliability of its financial information.
News